Aptevo Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
The following table summarizes the fees of Moss Adams LLP, our Independent Registered Public Accounting firm, billed to us for their audit and other services for the years ended December 31, 2023 and 2022. The audit fees include an estimate of amounts not yet billed.
For the years ended December 31, 2023 and 2022, fees paid or accrued to Moss Adams LLP were:
| Year Ended December 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| Audit Fees | $365,000 | $407,000 | ||
| Audit-related Fees | $ | - | $ | - |
| Tax Fees | $ | - | $ | - |
| All Other Fees | $ | - | $ | - |
| Total Fees | $365,000 | $407,000 | ||
Audit Fees. Audit fees consist of fees from our principal auditor for the audit of our consolidated financial statements and other professional services provided in connection with statutory and regulatory filings or engagements and comfort letters.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.